Skip to Main Content

Summary: Antibody-drug conjugates (ADCs) are a novel class of drugs that combine the potency of small molecule drugs with the targeting capabilities of highly-specific antibodies. While there is a wide array of different biochemical methods used for making ADCs, each method can have a varying effect on the stability of these types of therapeutics. In addition, the production of antibodies can be inherently complex and heterogeneous. Together, these challenges present a significant barrier to companies engaging in ADC drug development.

Click here for more information and to sign up today!

A novel ADC case study will be presented to highlight development success.


In this webinar you will learn:

  • ADC analytical characterization techniques and current regulatory expectations
  • Alternative approaches to quantitate ADC DAR.
  • Optimizing bench-scale conjugation.

Who should attend:

  • Analytical Development
  • Pharmaceutical Development
  • Process Development
  • Formulation Development

Speaker:

Benjamin Buer, Ph.D.

Associate Director of Pharmaceutical Development

Additional Articles

Pace Analytical® Acquires Aerobiology Laboratory Associates, Inc.

June 4, 2020

Pace Analytical® is First Commercial Laboratory to Test for COVID-19 in Wastewater

June 23, 2020